Skip to main content
SpringerLink
Log in

Irbesartan/Hydrochlorothiazide

In Moderate to Severe Hypertension

  • Adis Drug Profile
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

  • ▲ The fixed-dose combination of irbesartan/hydrochlorothiazide (HCTZ) is approved in the US for use as initial therapy in patients who are likely to need multiple agents to achieve their blood pressure (BP) goals.

  • ▲ In a 12-week, randomized, double-blind, multicentre trial in 538 patients with moderate hypertension that was untreated or uncontrolled by monotherapy, the mean reduction from baseline in seated systolic BP (SeSBP) at week 8 (primary endpoint) was significantly greater with irbesartan/HCTZ than with either irbesartan or HCTZ as monotherapy.

  • ▲ In addition, the proportion of patients with moderate hypertension achieving controlled BP (SeSBP <140 mmHg/seated diastolic BP [SeDBP] <90 mmHg) at 12 weeks was significantly greater with irbesartan/HCTZ combination therapy than with irbesartan or HCTZ monotherapy.

  • ▲ In a 7-week, randomized, double-blind, multicentre trial in 697 patients with severe hypertension that was untreated or uncontrolled by monotherapy, a significantly greater proportion achieved a trough SeDBP of <90 mmHg following 5 weeks of combination therapy with irbesartan/HCTZ compared with irbesartan monotherapy (primary endpoint).

  • ▲ Furthermore, the proportion of patients with severe hypertension achieving controlled BP of <140/ 90 mmHg was significantly greater at all timepoints of the trial compared with irbesartan monotherapy.

  • ▲ Irbesartan/HCTZ combination therapy had a similar tolerability profile to irbesartan and HCTZ monotherapy. Most adverse events were of mild to moderate intensity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Notes

  1. The use of trade names is for identification purposes only and does not imply endorsement.

References

  1. Mendis S, Lindholm LH, Mancia G, et al. World Health Organization (WHO) and International Society of Hypertension (ISH) risk prediction charts: assessment of cardiovascular risk for prevention and control of cardiovascular disease in low and middle-income countries. J Hypertens 2007 Aug; 25(8): 1578–82

    Article  PubMed  CAS  Google Scholar 

  2. Hajjar I, Kotchen JM, Kotchen TA. Hypertension: trends in prevalence, incidence, and control. Annu Rev Public Health 2006; 27: 465–90

    Article  PubMed  Google Scholar 

  3. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007 Jun; 28(12): 1462–536

    PubMed  Google Scholar 

  4. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003 Dec; 42(6): 1206–52

    Article  PubMed  CAS  Google Scholar 

  5. Staessen JA, O’Brien E. Will generic hypertension guidelines reduce the proliferation of directives? Heart 2007; 93: 775–7

    Article  PubMed  Google Scholar 

  6. Sanofi Avenus. Avalide (irbesartan-hydrochlorothiazide) tablets: US prescribing information [online]. Available from URL: http://www.sanofi-aventis.us [Accessed 2008 Mar 11]

  7. Croom KF, Curran MP, Goa KL, et al. Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy. Drugs 2004; 64(9): 999–1028

    Article  PubMed  CAS  Google Scholar 

  8. Saito F, Kimura G. Antihypertensive mechanism of diuretics based on pressure-natriuresis relationship. Hypertension 1996; 27: 914–8

    Article  PubMed  CAS  Google Scholar 

  9. Marino MR, Langenbacher KM, Ford NF, et al. Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of the angiotensin II blocker irbesartan. Clin Drug Invest 1997; 14(5): 383–91

    Article  CAS  Google Scholar 

  10. Marino MR, Lagenbacher K, Ford NF, et al. Pharmacokinetics and pharmacodynamics of irbesartan in healthy subjects. J Clin Pharmacol 1998; 38(3): 246–55

    PubMed  CAS  Google Scholar 

  11. Vachharajani NN, Shyu WC, Chando TJ, et al. Oral bioavailability and disposition characteristics of irbesartan, an angiotensin antagonist in healthy volunteers. J Clin Pharmacol 1998; 38(8): 702–7

    PubMed  CAS  Google Scholar 

  12. Patel RB, Patel UR, Rogge MC, et al. Bioavailability of hydrochlorothiazide from tablets and suspensions. J Pharm Sci 1984; 73(3): 359–61

    Article  PubMed  CAS  Google Scholar 

  13. Beermann B, Groschinsky-Grind M. Pharmacokinetics of hydrochlorothiazide in man. Eur J Clin Pharmacol 1977 Dec 2; 12(4): 297–303

    Article  PubMed  CAS  Google Scholar 

  14. Barbhaiya RH, Craig WA, Corrick-West HP, et al. Pharmacokinetics of hydrochlorothiazide in fasted and nonfasted subjects: a comparison of plasma level and urinary excretion methods. J Pharm Sci 1982; 71(2): 245–8

    Article  PubMed  CAS  Google Scholar 

  15. Whittaker A. A review of olmesartan medoxomil: a new angiotensin II receptor blocker. Br J Cardiol 2005; 12: 125–9

    Google Scholar 

  16. Chando TJ, Everett DW, Kahle AD, et al. Biotransformation of irbesartan in man. Drug Metab Dispos 1998; 26(5): 408–17

    PubMed  CAS  Google Scholar 

  17. Bourrie M, Meunier V, Berger Y, et al. Role of cytochrome P-450 2C9 in irbesartan oxidation by human liver microsomes. Drug Metab Dispos 1999; 27(2): 288–96

    PubMed  CAS  Google Scholar 

  18. Neutel JM, Franklin SS, Lapuerta P, et al. A comparison of the efficacy and safety of irbesartan/HCTZ combination therapy with irbesartan and HCTZ monotherapy in the treatment of moderate hypertension. J Hum Hypertens 2008; 22(11): 266–74

    Article  PubMed  CAS  Google Scholar 

  19. Neutel JM, Franklin SS, Oparil S, et al. Efficacy and safety of irbesartan/HCTZ combination therapy as initial treatment for rapid control of severe hypertension. J Clin Hypertens 2006; 8(12): 850–7

    Article  CAS  Google Scholar 

Download references

Acknowledgements and Disclosures

This article was reviewed by: G. Jerums, Endocrine Centre of Excellence, Austin Health, Repatriation Campus, Heidelberg, Victoria, Australia; C.E.S. Mogensen, Department of Diabetes and Endocrinology, Aarhus University Hospital, Aarhus, Denmark; G.L. Schwartz, Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, Minnesota, USA; J.A. Staessen, Laboratory of Hypertension, Campus Gasthuisberg, Leuven, Belgium.

The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Wolters Kluwer Health ¦ Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand

    Jamie D. Croxtall & Gillian M. Keating

  2. Wolters Kluwer Health, Conshohocken, Pennsylvania, USA

    Jamie D. Croxtall & Gillian M. Keating

Authors
  1. Jamie D. Croxtall
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gillian M. Keating
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jamie D. Croxtall.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Croxtall, J.D., Keating, G.M. Irbesartan/Hydrochlorothiazide. Drugs 68, 1465–1472 (2008). https://doi.org/10.2165/00003495-200868100-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200868100-00007

Keywords

Search

Navigation